Latest in Finance

Novo Nordisk acquires rights to Omeros’ MASP-3 inhibitor zaltenibart in $2.1bn deal

The agreement grants Novo Nordisk exclusive global rights to develop and commercialise the clinical-stage antibody for rare blood and kidney disorders, strengthening its Rare Disease portfolio

Find out more

Pharma leaders must separate AI hype from actionable opportunity, warns NIRAS

A new report from the company urges pharmaceutical executives to approach AI adoption with trust, transparency and traceability, outlining how the technology can drive...
See more

Kailera Therapeutics secures $600m in Series B financing to advance next-generation obesity therapies

The funding will support the advancement of Kailera’s obesity portfolio, including a global Phase III clinical programme of Kailera’s lead candidate KAI-9531, an injectable dual GLP-1/GIP receptor agonist with potentially best-in-category weight loss

LTS expands CDMO footprint with acquisition of Renaissance Lakewood

LTS Lohmann Therapie-Systeme has agreed to acquire US-based CDMO Renaissance Lakewood, strengthening its position in nasal spray and sterile dosage form manufacturing and broadening its global drug delivery capabilities

Nanoform collaborates with A.forall and IMGA to outlicence Nanoencorafenib

Nanoform will establish a new company, BRAFMed, to progress the clinical development and future outlicensing of the patient-centric nanoformulation of encorafenib

AstraZeneca strikes deal with US government to cut drug prices and boost domestic manufacturing

AstraZeneca has reached an agreement with the Trump administration to lower medicine costs, pledging $50bn in US manufacturing and R&D investment, whilst safeguarding the nation’s biopharma innovation leadership

Bristol Myers Squibb strengthens and diversifies cell therapy portfolio with acquisition of Orbital Therapeutics

Bristol Myers Squibb will acquire Orbital Therapeutics in a $1.5bn deal, adding next-generation RNA-based in vivo CAR T technology to its cell therapy pipeline and expanding treatment potential in autoimmune diseases

AstraZeneca to expand Virginia manufacturing facility with $4.5bn investment, creating 3600 jobs

AstraZeneca will develop a state-of-the-art manufacturing facility in Albemarle County, Virginia, producing a broader range of medicines, including weight management, metabolic and cancer therapies

Axplora announces €100m global investment drive to expand API and ADC manufacturing capacity

Axplora is investing more than €100m across its global network in 2025, with major projects in France, Italy and India aimed at strengthening small molecule API production and expanding antibody-drug conjugate capabilities to support future growth

Aseptic spray drying: Transforming biotherapeutics for a new era

With interest in aseptic spray drying on the rise in the pharmaceutical industry, Dr Kevin Robinson spoke to GEA’s David Costes about how the company is combining process, engineering and technological expertise with market insights to provide a safe, reliable and high-performance technology for advanced biotherapeutic powder applications

Latest posts in Finance

Owlstone Medical wins up to $49.1m award to develop at-home cancer detection tests

The breath and urine tests are part of the POSEIDON programme, which aims to enable accurate, low-cost, accessible cancer screening for all Americans

SeaBeLife raises €2 million to advance dual-target cell death therapies

The funding will help fast-track clinical trials for treatments addressing dry age-related macular degeneration and severe acute hepatitis, supporting the company’s innovative approach to blocking two major regulated cell death pathways

Daiichi Sankyo launches third global research institute in San Diego

The company expands its international research footprint with a new San Diego institute, strengthening collaborations in one of the world’s leading life-science hubs and advancing its global drug discovery strategy

Nanologica secures first insulin purification order in China

The SEK 2m deal will see the company’s silica-based NLAB Saga evaluated at production scale by a Chinese insulin manufacturer

Symbiosis expands sterile manufacturing capacity with fill/finish line qualification

Symbiosis has maintained a track record of successful GMP inspections with both the FDA and MHRA since it was founded

Genmab to acquire Merus in $8bn deal to expand late-stage pipeline

The acquisition adds breakthrough therapy petosemtamab to Genmab’s portfolio, accelerating its shift to a wholly owned model and supporting multiple new drug launches by 2027

New CGT centre in Bangkok to boost Southeast Asia’s biotech ecosystem

eXmoor Pharma and Siam Bioscience form a strategic partnership to establish leading cell and gene therapy services in Southeast Asia

Pfizer to acquire Metsera in $4.9bn deal, expanding obesity drug pipeline with next-generation incretin and amylin therapies

The deal strengthens Pfizer’s position in the fast-growing obesity market, with additional milestone payments of up to $2.3bn tied to key clinical and regulatory achievements

DaltonTx secures £4m in seed financing to build adaptive, AI-enabled discovery platforms

The UK-based technology company's adaptive platform will plug directly into pharma, biotech and CRO workflows, giving teams instant access to AI-enabled discovery

Prange Pharma to acquire MSD Animal Health manufacturing site in Aprilia, Italy

Following completion, the site will relaunch as Aprilia Animal Health, focussing on contract manufacturing of animal health products whilst preserving jobs and expanding European expertise

EMV Capital subsidiary Moirai acquires Destiny Pharma’s XF-73 antibiotic platform

The XF drug platform, designed to prevent bacterial resistance and combat Gram-positive infections such as MRSA, represents a high-impact addition to EMV’s life sciences portfolio

Sponsor content

Gerresheimer adjusts 2025 guidance amid slower market growth

Transformation program launched to boost performance and free cash flow

GEA raises guidance following strong H1 performance

Revised forecast reflects improved margins, robust order intake and efficiency gains

Lonza delivers strong H1 2025 performance

Lonza delivers strong H1 2025 performance and upgrades 2025 full-year CDMO sales and margin outlook

Gerresheimer reports H1 2025 growth driven by Bormioli Pharma acquisition

Cosmetics and oral liquids markets dampen organic revenue but outlook remains strong

Almac completes a multi-million-pound investment enhancing cold chain capabilities in Craigavon

Almac Clinical Services, part of the Almac Group, has completed a multi-million-pound investment to enhance cold chain capabilities at its global headquarters in...

CARBOGEN AMCIS accelerates manufacturing capacity with CHF 25.5 million co-investment at Swiss sites

CARBOGEN AMCIS is pleased to announce a strategic co-investment of more than CHF 25 million with a long-standing Japanese customer to expand manufacturing capabilities at...

Gerresheimer adjusts guidance for Financial Year 2025

Gerresheimer is adjusting its guidance for 2025 due to continuing subdued demand in the cosmetics market and a decline in demand for plastic containment solutions for oral...

Almac Group hits record £1 billion revenue milestone

Strong financials support expansion in manufacturing and clinical capabilities

Lonza publishes updated 2024 financials ahead of One Lonza reporting

New CDMO platform structure supports upcoming half-year 2025 results

Vetter once again named best managed company

The award jury recognises strategic and sustainable corporate management

SCHOTT Pharma delivers strong second quarter of fiscal year 2025

SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, today published its results for the second quarter of the fiscal year 2025

Gerresheimer: Bormioli Pharma boosts revenues and earnings

Gerresheimer recorded a jump in revenues and earnings due to the first-time consolidation of Bormioli Pharma, which was acquired in 2024